EFG Asset Management North America Corp. Sells 25,003 Shares of Halozyme Therapeutics, Inc. $HALO

EFG Asset Management North America Corp. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,436 shares of the biopharmaceutical company’s stock after selling 25,003 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Halozyme Therapeutics were worth $5,825,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $25,000. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $32,000. Employees Retirement System of Texas bought a new position in Halozyme Therapeutics during the 2nd quarter worth $34,000. Finally, First Horizon Corp acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $56,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Friday, December 19th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Morgan Stanley cut their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $78.80.

Insider Transactions at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 4,263 shares of the business’s stock in a transaction on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. The trade was a 25.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 45,661 shares of company stock valued at $3,139,257. Corporate insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $69.87 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company has a market cap of $8.22 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 0.30 and a beta of 0.94. The company has a 50 day moving average of $68.76 and a 200-day moving average of $68.11. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same period last year, the firm posted $1.27 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.